A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study

CONCLUSION: s : The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.PMID:38031473 | DOI:10.5045/br.2023.2023206

Source: Blood Research - November 30, 2023 Category: Hematology Authors: Seok Jin Kim Young Rok Do Ho-Sup Lee Won-Sik Lee Jee Hyun Kong Jae-Yong Kwak Hyeon-Seok Eom Joon Ho Moon Jun Ho Yi Jeong-Ok Lee Jae-Cheol Jo Deok-Hwan Yang Source Type: research